TXG (10x Genomics, Inc. Class A Common Stock) Stock Analysis - Financials
10x Genomics, Inc. Class A Common Stock (TXG) is a publicly traded Healthcare sector company. As of May 21, 2026, TXG trades at $23.64 with a market cap of $2.72B and a P/E ratio of -137.82. TXG moved +7.58% today. Year to date, TXG is +30.90%; over the trailing twelve months it is +164.10%. Its 52-week range spans $6.78 to $26.45. Analyst consensus is buy with an average price target of $24.10. Rallies surfaces TXG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What are TXG's key financials?
TXG financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TXG recently traded at $23.64. Market cap is $2.72B. P/E ratio is -137.82. Revenue is $638.78M.
TXG financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TXG recently traded at $23.64. Market cap is $2.72B. P/E ratio is -137.82. Revenue is $638.78M.
Is TXG research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TXG. It does not provide personalized investment advice.